CL2014003078A1 - Homodimero de una proteínas del factor 21 de crecimiento del fibroblasto (fgf21); molecula de adn que la codifica; proceso para producirla y sus uso. - Google Patents

Homodimero de una proteínas del factor 21 de crecimiento del fibroblasto (fgf21); molecula de adn que la codifica; proceso para producirla y sus uso.

Info

Publication number
CL2014003078A1
CL2014003078A1 CL2014003078A CL2014003078A CL2014003078A1 CL 2014003078 A1 CL2014003078 A1 CL 2014003078A1 CL 2014003078 A CL2014003078 A CL 2014003078A CL 2014003078 A CL2014003078 A CL 2014003078A CL 2014003078 A1 CL2014003078 A1 CL 2014003078A1
Authority
CL
Chile
Prior art keywords
fgf21
homodimer
encodes
protein
produce
Prior art date
Application number
CL2014003078A
Other languages
English (en)
Inventor
Craig Duane Dickinson
David Albert Driver
Malgorzata Donata Gonciarz
Ryan James Darling
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48670814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003078(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2014003078A1 publication Critical patent/CL2014003078A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/813—Carrier is a saccharide
    • Y10S530/814—Cellulose or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL2014003078A 2012-06-11 2014-11-13 Homodimero de una proteínas del factor 21 de crecimiento del fibroblasto (fgf21); molecula de adn que la codifica; proceso para producirla y sus uso. CL2014003078A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261658104P 2012-06-11 2012-06-11
US201361777386P 2013-03-12 2013-03-12

Publications (1)

Publication Number Publication Date
CL2014003078A1 true CL2014003078A1 (es) 2015-02-27

Family

ID=48670814

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003078A CL2014003078A1 (es) 2012-06-11 2014-11-13 Homodimero de una proteínas del factor 21 de crecimiento del fibroblasto (fgf21); molecula de adn que la codifica; proceso para producirla y sus uso.

Country Status (24)

Country Link
US (2) US8741841B2 (es)
EP (1) EP2858662B1 (es)
JP (1) JP6182600B2 (es)
KR (1) KR20150006060A (es)
CN (1) CN104394882B (es)
AR (1) AR091216A1 (es)
AU (1) AU2013274638A1 (es)
BR (1) BR112014029966A2 (es)
CA (1) CA2871145A1 (es)
CL (1) CL2014003078A1 (es)
CO (1) CO7151525A2 (es)
EA (1) EA201492053A1 (es)
EC (1) ECSP14030742A (es)
ES (1) ES2644787T3 (es)
HK (1) HK1203357A1 (es)
IL (1) IL235832A0 (es)
IN (1) IN2014MN02132A (es)
MX (1) MX2014015257A (es)
PE (1) PE20150201A1 (es)
PH (1) PH12014502766A1 (es)
SG (1) SG11201408095XA (es)
TN (1) TN2014000439A1 (es)
TW (1) TWI513705B (es)
WO (1) WO2013188181A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
WO2013006486A2 (en) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
CA2871656A1 (en) * 2012-06-11 2013-12-19 Eli Lilly And Company Fibroblast growth factor 21 variants
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
HK1214832A1 (zh) 2012-11-28 2016-08-05 恩格姆生物制药公司 用於代謝病症和疾病治療的組合物和方法
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
MX383664B (es) 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2015065897A1 (en) 2013-10-28 2015-05-07 Ngm Biopharmaceuticals, Inc. Cancer models and associated methods
PT3097122T (pt) 2014-01-24 2020-07-21 Ngm Biopharmaceuticals Inc Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos
EP3107937A4 (en) 2014-02-21 2017-11-15 MedImmune, LLC Anti-pcsk9~glp-1 fusions and methods for use
US20170065678A1 (en) 2014-03-11 2017-03-09 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
CA2943355C (en) 2014-03-25 2023-09-05 Regeneron Pharmaceuticals, Inc. Fgf21 receptor agonists and uses thereof
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
JP6308699B2 (ja) * 2014-09-08 2018-04-11 国立大学法人大阪大学 脱髄疾患の予防又は治療剤
CN114129709A (zh) 2014-10-23 2022-03-04 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
SMT202100388T1 (it) 2014-10-24 2021-09-14 Bristol Myers Squibb Co Polipeptidi fgf-21 modificati e loro usi
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
KR20160088656A (ko) * 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
US11638745B2 (en) 2015-05-20 2023-05-02 University of Pittsburgh—Of the Commonwealth Cvctom of Hierher Education Method to improve neurologic outcomes in temperature managed patients
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
KR102668200B1 (ko) 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
KR102670157B1 (ko) 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
CN105348380B (zh) * 2015-12-28 2019-03-01 江苏康缘瑞翱生物医药科技有限公司 犬成纤维细胞生长因子21及其在治疗犬内分泌疾病中的用途
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
CN107759697B (zh) 2016-08-19 2023-03-24 安源医药科技（上海）有限公司 制备融合蛋白的方法
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
AU2017358289C1 (en) * 2016-11-10 2025-05-08 Yuhan Corporation Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
EP4470551A3 (en) 2017-03-14 2025-02-26 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
CN110709520B (zh) 2017-04-21 2024-04-05 株式会社柳韩洋行 用于产生双功能蛋白质及其衍生物的方法
CN107385020A (zh) * 2017-06-23 2017-11-24 西安医学院 瘦素在人重组fgf21蛋白活性检测中的应用
MX2020002206A (es) 2017-09-08 2020-07-20 Bristol Myers Squibb Co Factor de crecimiento de fibroblastos 21 (fgf-21) modificado para usarse en metodos para tratar la esteatohepatitis no alcoholica (nash).
US20200376080A1 (en) 2017-12-22 2020-12-03 Novartis Ag Methods of treating metabolic disorders with fgf21 variants
AU2019218147B2 (en) 2018-02-08 2023-06-08 Sunshine Lake Pharma Co., Ltd. FGF21 variant, fusion protein and application thereof
CA3104686A1 (en) 2018-07-03 2020-01-09 Bristol-Myers Squibb Company Fgf-21 formulations
CN111195234B (zh) * 2018-11-16 2022-08-26 鲁南制药集团股份有限公司 一种重组FGF21-Fc融合蛋白冻干粉制剂
CN111662373B (zh) * 2019-03-05 2024-05-14 广东东阳光药业股份有限公司 一种多肽分子及其应用
JP2022530216A (ja) * 2019-04-23 2022-06-28 エルジー・ケム・リミテッド 免疫グロブリンのＦｃ領域およびＧＤＦ１５を含む融合ポリペプチド
IL294534A (en) 2020-01-08 2022-09-01 Bristol Myers Squibb Co Fgf-21 conjugate formulations
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
JP2023538533A (ja) 2020-08-07 2023-09-08 ブリストル－マイヤーズ スクイブ カンパニー 線維症の処置のための、ｃｃｒ２／５拮抗剤と組み合わせたｆｇｆ２１
KR20220021207A (ko) 2020-08-13 2022-02-22 주식회사 나이벡 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물
KR102495299B1 (ko) * 2020-11-03 2023-02-06 토드제약 주식회사 Fgf21의 열탄력성을 이용한 fgf21 생산 방법
US20240123031A1 (en) 2020-11-25 2024-04-18 Bristol-Myers Squibb Company Methods of treating liver diseases
KR102631925B1 (ko) * 2021-06-10 2024-02-01 토드제약 주식회사 신규 fgf21 변이체 개발 및 이의 생산기법과 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
CN1890371A (zh) 2003-12-10 2007-01-03 伊莱利利公司 成纤维细胞生长因子的21突变蛋白
SI1751184T1 (sl) 2004-05-13 2010-01-29 Lilly Co Eli Fgf-21 fuzijski proteini
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
EP2296690B1 (en) * 2008-06-04 2016-11-30 Amgen, Inc Fgf21 mutants and uses thereof
CH699521A2 (de) 2008-09-09 2010-03-15 Rotorcraft Ag Streckwerk für eine Strickmaschine.
JP5878757B2 (ja) 2008-10-10 2016-03-08 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
WO2010065439A1 (en) * 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
BRPI1007313A2 (pt) 2009-01-23 2016-02-10 Novo Nordisk As derivados de fgf21 com ligante de albumina a-b-c-d-e e seu uso.
EP2427207B1 (en) 2009-05-05 2017-08-16 Amgen, Inc Fgf21 mutants and uses thereof
HRP20240135T1 (hr) 2009-05-05 2024-04-12 Amgen Inc. Fgf21 mutanti i njihove upotrebe
WO2011154349A2 (en) * 2010-06-08 2011-12-15 Novo Nordisk A/S Fgf21 analogues and derivatives
AR087973A1 (es) 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質

Also Published As

Publication number Publication date
EA201492053A1 (ru) 2015-02-27
JP6182600B2 (ja) 2017-08-16
HK1203357A1 (en) 2015-10-30
CO7151525A2 (es) 2014-12-29
IL235832A0 (en) 2015-01-29
US8741841B2 (en) 2014-06-03
KR20150006060A (ko) 2015-01-15
BR112014029966A2 (pt) 2017-09-12
CN104394882A (zh) 2015-03-04
IN2014MN02132A (es) 2015-09-11
CA2871145A1 (en) 2013-12-19
AU2013274638A1 (en) 2014-11-06
SG11201408095XA (en) 2015-01-29
AR091216A1 (es) 2015-01-21
EP2858662B1 (en) 2017-08-09
MX2014015257A (es) 2015-03-05
TW201408693A (zh) 2014-03-01
US20140228282A1 (en) 2014-08-14
TN2014000439A1 (en) 2016-03-30
WO2013188181A1 (en) 2013-12-19
EP2858662A1 (en) 2015-04-15
US20130330336A1 (en) 2013-12-12
US8927492B2 (en) 2015-01-06
PE20150201A1 (es) 2015-02-19
ES2644787T3 (es) 2017-11-30
PH12014502766A1 (en) 2015-02-09
ECSP14030742A (es) 2015-09-30
JP2015527974A (ja) 2015-09-24
CN104394882B (zh) 2016-06-22
TWI513705B (zh) 2015-12-21

Similar Documents

Publication Publication Date Title
CL2014003078A1 (es) Homodimero de una proteínas del factor 21 de crecimiento del fibroblasto (fgf21); molecula de adn que la codifica; proceso para producirla y sus uso.
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
MX2020009401A (es) Ligadores de nucleótidos modificados.
CL2014002846A1 (es) Usos terapéuticos de proteínas del factor de crecimiento del fibroblasto 21.
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
EA201690671A1 (ru) Пустотные изделия и композиционные материалы, способы их производства и применения
BR112014027544A2 (pt) composição cosmética, processo cosmético e uso cosmético.
EA201171148A1 (ru) Антитело-антагонист, специфичное для гетеродимера альфа-4-бета-7
DK2831241T3 (da) Kunstige nukleinsyremolekyler til forbedret protein- eller peptidekspression.
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
EP3426270A4 (en) A TRANSITIONAL COMMENSAL MICROORGANISM TO IMPROVE INTESTINAL HEALTH
DOP2013000178A (es) Tratamiento de la osteoartritis y del dolor
DK2938740T3 (da) Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser
MX375524B (es) Anticuerpos anti-axl.
MX379312B (es) Anticuerpos especificos para fcrn.
EA201391041A1 (ru) Растворимые в воде мембранные белки и способы их получения и применения
BR112014026815A2 (pt) composição cosmética, processo cosmético e uso de uma composição cosmética
AR095977A1 (es) Un procedimiento para aumentar la formación de ácido piroglutámico de una proteína
EA201600252A1 (ru) Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
MX389359B (es) Uso terapeutico de la proteina de union a neurotrofina p75ntr.
BR112015010525A2 (pt) processo para alisamento de fibras de queratina, uso de uma composição e composição cosmética.
CR20150554A (es) Elementos regulatorios de planta y sus usos
DOP2016000202A (es) Proteínas de fusión uti
BR112014026795A2 (pt) composição cosmética , processo cosmético para tratar a matéria queratínica e uso de uma composição cosmética.
ITUB20152355A1 (it) Dispositivo di illuminazione, ad esempio per l'illuminazione di serre, e corrispondente procedimento di impiego